Biotechnology
Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
ROCKVILLE, Md. and SUZHOU, China, March 27, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology a...
2024-03-27 08:00
1848
World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain
LONDON, March 27, 2024 /PRNewswire/ -- Lightpoint Surgical Limited (Lightpoint), an affiliate of Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a world-first bladder cancer sentinel lymph node (SLN) procedure with SENSEI®, Telix's miniature robotic-assisted gamma pro...
2024-03-27 05:59
983
ReportLinker Reveals Key Insights About Players and Coverage in Latest Combination Vaccine Market Analysis
LYON, France, March 26, 2024 /PRNewswire/ -- Reportlinker announces the release
of the report "A White Paper To Understand The Market Structure Of Pediatric
Pertussis Hexavalent and Combination Vaccines
2024-03-26 21:00
1101
Alphamab Oncology Announces the First Patient Dosed in Australia in the Clinical Study of Subcutaneous Formulation JSKN033
SUZHOU, China, March 26, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been dosed inAustralia in the clinical study (JSKN033-101) of JSKN033, a subcutaneous formulation with HER2 bispecific antibody-conjugated drug and PD-L1 monoclonal antibody,...
2024-03-26 09:57
1497
Scivita Medical Expands Collaboration with Boston Scientific
SUZHOU, China, March 26, 2024 /PRNewswire/ -- Recently, Scivita Medical
Technology Co., Ltd. ("Scivita Medical") and Boston
Scientific Corporation (NYSE: BSX), a leading global medical technology
company, joined hands again to sign an expanded strategic cooperation
arrangement.
2024-03-26 09:30
1562
BioDuro-Sundia's Partner, DigmBio Announced IND Clearance from Korea MFDS for its Selective PARP1 Inhibitor DM5167
SHANGHAI, March 26, 2024 /PRNewswire/ -- BioDuro-Sundia's partner, DigmBio, a South Korean biotechnology company, announced its selective PARP1 inhibitor for the treatment of triple-negative breast cancer has been approved by Korea Food and Drug Administration (MFDS) for Investigational New Drug ...
2024-03-26 08:30
1631
Medipledge, a premium post-laser skincare brand, just launched in Australia
SYDNEY, March 25, 2024 /PRNewswire/ -- On March 24th, 2024, Medipledge, a premium skincare brand developed by experts in beauty and dermatology, successfully launched inAustralia. The launch event, held in Australia, featured high-tech elements and included high-end aesthetic therapists, lead...
2024-03-25 10:09
1264
Advancing Healthcare Innovation: Juniper Biologics Recognized as the Best Novel Therapy R&D and Commercialization Company 2024 by APAC Insider
SINGAPORE, March 25, 2024 /PRNewswire/ -- Juniper Biologics
2024-03-25 09:51
1176
Veeva Vault EDC Surpasses 1,000 Study Start Milestone
Eight of the top 20 biopharmas standardize on Vault EDC to build a modern
clinical data foundation
SINGAPORE, March 25, 2024 /PRNewswire/ -- Veeva Systems
2024-03-25 08:00
2089
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational strategy Integrating R&D, manufacturing and commercial upsides by acquiring full intellectual property rights of BRII-179 and expanding it...
2024-03-22 19:00
4126
The Results of Phase II Clinical Study of KN046 Plus Chemotherapy as First-line Treatment for Metastatic NSCLC were Published in Cell Reports Medicine
SUZHOU, China, March 22, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the phase II clinical research results of anti- PD-L1/CTLA-4 bispecific antibody KN046 plus chemotherapy as first-line treatment for metastatic non-small cell lung cancer (NSCLC) were published o...
2024-03-22 18:42
2871
Antengene Announces Full Year 2023 Financial Results, Highlights Clinical Progress Across First-in-Class, Best-in-Class Pipeline
* Promising clinical activities and efficacies during dose escalations for four lead global rights programs targeting CD24, Claudin 18.2, CD73, and PD-L1/4-1BB * Positive, differentiated cervical cancer data advancing mTORC1/2 inhibitor on registrational track for APAC markets * RMB1.188 bi...
2024-03-22 18:00
6336
NeuExcell Therapeutics Announces Successful Dosing of First Patient by NeuroD1 Gene Therapy
SUZHOU, China, March 22, 2024 /PRNewswire/ -- NeuExcell Therapeutics, a leading biotechnology company focused onin vivo neural regenerative therapies, announces the successful dosing of the first patient with the first-in-class NeuroD1 gene therapy product NXL-004. This milestone represents si...
2024-03-22 08:00
2330
Henlius 2023 Annual Results: Revenue surpassed RMB5.39 billion with a net profit RMB546 million, first full-year profitability achieved
SHANGHAI, March 21, 2024 /PRNewswire/ -- Henlius (2696.HK) announced its 2023 annual results. During the reporting period, Henlius' revenue reached about RMB5.3949 billion, representing an increase of 67.8% YoY, and recorded a net profit ofRMB546.0 million. This is the first time for Henlius to a...
2024-03-21 19:47
3802
SK bioscience Exports Influenza Vaccine to Thailand, Entering Southern Hemisphere Market
* Company exported 440,000 doses to Thailand, marking its entry into the Southeast Asian market and the Southern Hemisphere market. * Company has obtained marketing authorizations in 12 countries, with additional approvals underway in 10 countries to expand its market worldwide. BANGKOK and S...
2024-03-21 13:24
2172
TreeFrog's Chief Scientific Officer & Co-founder, Maxime Feyeux, to present at The 23rd Congress of the Japanese Society for Regenerative Medicine (JSRM)
- TreeFrog Therapeutics demonstrates fast, sustained, full motor recovery in preclinical models for Parkinson's Disease cell therapy program using C-Stem™ proprietary technology[1] - BORDEAUX, France, March 21, 2024 /PRNewswire/ -- TreeFrog Therapeutics, a cell therapy development company with...
2024-03-21 07:30
1929
Jiangsu Recbio Technology Co., Ltd. announced 2023 annual results report and latest progress
TAIZHOU, China, March 21, 2024 /PRNewswire/ -- Innovative vaccine company Recbio (02179.HK) announced its latest progress and annual results for 2023. The company always adhered to the mission of " Protect Human Health With Best-In-Class Vaccines", and achieved the following milestones and progre...
2024-03-21 00:22
3461
Antengene Initiates Phase II Dose Expansion Study of Claudin 18.2 ADC ATG-022 in China and Australia
SHANGHAI and HONG KONG, March 20, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in he...
2024-03-20 20:30
2630
Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study
* ATN-031 (also known as ATG-031), is the first anti-CD24 antibody to advance to the clinic in oncology inthe United States * The Phase I PERFORM trial, ongoing at four major U.S. cancer centers, is evaluating the safety and preliminary efficacy of ATN-031 in patients with advanced solid tumor...
2024-03-20 20:30
2522
Innovent Announces 2023 Annual Results and Business Updates
A transformative year of strong performance and material innovation progress ROCKVILLE, M.D. and SUZHOU, China, March 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality med...
2024-03-20 19:44
4118
Week's Top Stories
Most Reposted
ASTON MARTIN ARAMCO FORMULA ONE® TEAM ANNOUNCE PEPPERSTONE AS OFFICAL TRADING PARTNER
[Picked up by 308 media titles]
2025-01-07 09:00
Brewing Connections and Spotlighting Café Culture: MIFB 2025 Hosts MNCC in Collaboration with MSCA
[Picked up by 307 media titles]
2025-01-06 14:00
RuggON Unveils VORTEX Vehicle Mount Computer with AI-Enhanced, SATCOM-Ready
[Picked up by 306 media titles]
2025-01-06 21:00
iWOW Unveils Age-Tech Innovations at CES 2025, Expanding Portfolio of IoT Solutions for Ageing-In-Place
[Picked up by 294 media titles]
2025-01-07 21:18CELEBRATE THE LUNAR NEW YEAR 2025 AT HOIANA RESORT & GOLF, WORLD'S LEADING FULLY INTEGRATED RESORT
[Picked up by 292 media titles]
2025-01-06 19:25
Most Read
Hyundai Motor Group Partners with NVIDIA to Accelerate Development of AI Solutions for Future Mobility
2025-01-10 01:00
18611
ASTON MARTIN ARAMCO FORMULA ONE® TEAM ANNOUNCE PEPPERSTONE AS OFFICAL TRADING PARTNER
2025-01-07 09:00
5186